IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Average Recommendation of "Moderate Buy" by Brokerages

IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Get Free Report) has been assigned an average rating of "Moderate Buy" from the thirteen research firms that are covering the firm, Marketbeat reports. Three investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $47.55.

IDYA has been the topic of several research reports. JPMorgan Chase & Co. boosted their target price on IDEAYA Biosciences from $63.00 to $66.00 and gave the company an "overweight" rating in a research note on Thursday, May 22nd. The Goldman Sachs Group initiated coverage on IDEAYA Biosciences in a research note on Thursday. They issued a "neutral" rating and a $25.00 target price on the stock. Wells Fargo & Company initiated coverage on IDEAYA Biosciences in a research note on Thursday, June 26th. They issued an "overweight" rating and a $44.00 target price on the stock. Finally, Royal Bank Of Canada upgraded IDEAYA Biosciences from an "outperform" rating to a "moderate buy" rating and cut their target price for the company from $57.00 to $30.00 in a research note on Wednesday.

IDEAYA Biosciences Price Performance

NASDAQ:IDYA opened at $22.80 on Friday. IDEAYA Biosciences has a fifty-two week low of $13.45 and a fifty-two week high of $44.42. The stock has a market capitalization of $2.00 billion, a PE ratio of -6.35 and a beta of 0.03. The business's 50-day simple moving average is $20.51 and its 200-day simple moving average is $20.53.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($0.82) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.07). During the same quarter last year, the company posted ($0.53) earnings per share. On average, research analysts expect that IDEAYA Biosciences will post -3.07 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in shares of IDEAYA Biosciences by 9.1% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 7,483 shares of the company's stock worth $123,000 after acquiring an additional 627 shares during the last quarter. Daiwa Securities Group Inc. increased its holdings in shares of IDEAYA Biosciences by 44.0% during the 4th quarter. Daiwa Securities Group Inc. now owns 2,792 shares of the company's stock worth $72,000 after acquiring an additional 853 shares during the last quarter. Mariner LLC increased its holdings in shares of IDEAYA Biosciences by 9.8% during the 4th quarter. Mariner LLC now owns 9,775 shares of the company's stock worth $251,000 after acquiring an additional 869 shares during the last quarter. Swiss National Bank increased its holdings in shares of IDEAYA Biosciences by 0.8% during the 1st quarter. Swiss National Bank now owns 150,800 shares of the company's stock worth $2,470,000 after acquiring an additional 1,200 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of IDEAYA Biosciences by 6.0% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 21,301 shares of the company's stock worth $349,000 after acquiring an additional 1,214 shares during the last quarter. Institutional investors and hedge funds own 98.29% of the company's stock.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.